<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D48FC12-E560-4B37-9CF3-48B80B7FF457"><gtr:id>8D48FC12-E560-4B37-9CF3-48B80B7FF457</gtr:id><gtr:name>Institute of Genetics, Molecular and Cellular Biology (IGBMC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D48FC12-E560-4B37-9CF3-48B80B7FF457"><gtr:id>8D48FC12-E560-4B37-9CF3-48B80B7FF457</gtr:id><gtr:name>Institute of Genetics, Molecular and Cellular Biology (IGBMC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6F3C80C5-1E93-4E7B-A050-C6C768F1632C"><gtr:id>6F3C80C5-1E93-4E7B-A050-C6C768F1632C</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Festenstein</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F182"><gtr:id>9BBBC739-7D3E-4A1E-8BC3-A61314D21287</gtr:id><gtr:title>Unravelling heterochromatin in health and disease: investigating position effect variegation and LCR function in mammals</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/182</gtr:grantReference><gtr:abstractText>The development of all animals requires a highly coordinated process of gene regulation. The body consists of billions of cells and many different cell types. Each cell contains all the genes derived from the fertilised egg. During development individual cells take the decision to activate or silence specific genes defining the individual identity of different cell types. We will study the way cells make the decision to switch on genes in particular cell types and remember this decision. We have discovered that key aspects of this process are shared between fruit flies and mammals. When the gene which encodes the uniform red eye colour in fruit flies is abnormally packaged by translocating too close to a highly repetitive region of the DNA code it switches off in some cells but not others. Once the decision is made this is passed on to the daughter cells producing patches of red and white cells in the eye. This phenomenon has provided essential information about how packaging genes in chromatin can lead to their silencing or activation. We have discovered a similar phenomenon in mice which are much closer to humans. Our findings show that in several human diseases caused by abnormally expanded repetitive DNA genes may be switched off using a similar mechanism. The proposal is to investigate both the way genes are normally regulated by such packaging and how we can influence this. We will determine whether we can switch a gene back on that has been abnormally silenced in the human disease Friedreich?s ataxia and whether we can switch off a an abnormally toxic gene in a common adult form of muscular dystrophy -Myotonic Dystrophy. Most of the studies will use mouse models or cells derived from patients. We hope that by understanding the ways that genes are normally switched on and off in mice we can develop better strategies for treating disease in humans.</gtr:abstractText><gtr:technicalSummary>There is a stringent requirement for highly efficient gene silencing and co-ordinated gene activation during cellular differentiation. Our experiments on the regulation of the human CD2 (hCD2) gene (consitutively expressed on T cells) revealed that its locus control region (LCR) could overcome the repressive effects imposed by heterochromatin in transgenic mice. Disabling the LCR, by deleting a small subregion, had no effect on the level of expression per cell but resulted in silencing of transgene expression in a proportion of T cells when the transgene was integrated near heterochromatin. This phenomenon shares several essential features with position effect variegation (PEV), which was first identified when the Drosophila white gene (encoding for uniform red eye) was translocated close to the centromere leading to variegated red and white patches in the eye. Variable spreading of heterochromatin from the centromere to shut down the nearby white gene in some cells but not others was invoked as an explanation. This implied that once the decision to express or not was made this information was ?locked-in? and passed on to the daughter cells. Genetic mutagenesis studies on PEV have been crucial in identifying key factors required for the establishment, maintenance and heritability of gene expression states at the level of DNA packaging into chromatin. The hCD2 system is providing an ideal means to study the function of these factors in mammals. Establishing a link between PEV and LCRs has allowed me to formulate and test a probabiltiy model for LCR function. The extent of silencing can be modulated in vivo by altering the dosage of several mammalian homolgues of key modifiers of PEV in Drosophila. Moreover, we are studying factor-binding sites within the LCR that are required to fully prevent PEV. We recently showed that triplet-repeat expansions found in several diseases can induce PEV indicating that PEV-modifiers are potential human disease modifier genes, a hhesis that is being addressed using triplet-repeat ?knockin? mice and cells from patients. We will continue our studies on the molecular mechanisms underlying LCR function and how gene expression states are established and maintained by studying which chromatin modifications and DNA sequences are required for somatic heritability of such states in vivo. Our recent observations indicate that heterochromatin is more dynamic than previously thought and that heterochromatin-mediated silencing can be overcome in vitro and in vivo. Such manipulations may form the basis for new therapeutic avenues in diseases caused by abnormal gene silencing. Moreover, understanding LCR function will be important for achieving reliable and stable tissue-specific gene expression in somatic gene therapy.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1375828</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Adolf Butenandt Institute</gtr:department><gtr:description>AI</gtr:description><gtr:id>53EE04B0-D58C-4A34-9796-CC64F1916060</gtr:id><gtr:impact>With the expertise provided we were able to confirm that the novel modification is present in a diverse range of eukaryotes.</gtr:impact><gtr:outcomeId>E45764435B1-1</gtr:outcomeId><gtr:partnerContribution>Mass spectometry for histone modifications</gtr:partnerContribution><gtr:piContribution>We developed an anitbody which enabled identification of a novel histone modification.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>PB</gtr:description><gtr:id>390F6823-0A12-4293-8358-0BC5F834602F</gtr:id><gtr:impact>Revealed autosomal genes that are sensitive to sex chromosome complement rather than gender, publications in preparation.</gtr:impact><gtr:outcomeId>9AEE8D3AB65-1</gtr:outcomeId><gtr:partnerContribution>Provision of specialised murine lines</gtr:partnerContribution><gtr:piContribution>Crossing of hCD2 variegating lines to the four core genotypes model and analysis of gene expression</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Genetics and Molecular and Cellular Biology (IGBMC)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>HP</gtr:description><gtr:id>8498239D-2402-4E78-A27D-3711C4A988A1</gtr:id><gtr:impact>Production of cell lines from patients for further charactersitaion of effect of therapies on epigenoptype</gtr:impact><gtr:outcomeId>E059E2895EE-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise and training to produce IPS cells from patients with FRDA</gtr:partnerContribution><gtr:piContribution>We have developed chromatin immunoprecipitation techniques to anlyse the epigenotype in FRDA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FS</gtr:description><gtr:id>DBA9004C-BF23-4EE8-A9B6-CFD912E04541</gtr:id><gtr:impact>We have made target constructs to mutate key chromatin components in vivo and produced murine ES cell lines.</gtr:impact><gtr:outcomeId>515958BB90A-1</gtr:outcomeId><gtr:partnerContribution>transfer of advanced bacterial recombineering technology by training a research assistant</gtr:partnerContribution><gtr:piContribution>Terchnology transfer of advanced techniques in bacterial recombineering</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GMEC Rare Disease Consortium</gtr:description><gtr:id>E333A1E7-2D6B-4773-ACFF-8783A9E552E5</gtr:id><gtr:impact>Mitochondrial funcction, FXN gene regulation, epigenetics</gtr:impact><gtr:outcomeId>56c2f5e0f0afc9.87542111-1</gtr:outcomeId><gtr:partnerContribution>Collaboration between Oxford University, UCL and Imperial on clinical and basic research aspects of Friedreich's ataxia</gtr:partnerContribution><gtr:piContribution>Friedreich's ataxia research on novel therapeutics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Symposium on epigenetics and disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>09088B6B-6A0F-4EBB-8D38-D3FD99810FDF</gtr:id><gtr:impact>approx. 250 people attended a vibrant and fascinating meeting on the interface between epigenetics and understanding disease

Experts in the field holding an open scientific meeting fostering science and public engagement</gtr:impact><gtr:outcomeId>gTFEHBzjuqH</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.college-de-france.fr/site/en-jean-louis-mandel/seminar-2013-05-21-09h00.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV-interview Dublin</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4B37A7D5-66E4-4182-8AD7-EA53CEDB1A70</gtr:id><gtr:impact>Interviewed at International conference for Friedreich's Ataxia

Raised the profile of the need for research in triplet-repeat diseases</gtr:impact><gtr:outcomeId>EBF11CCDC95</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV documentary</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D8FF8636-4902-4453-8124-ED2A6507F8D1</gtr:id><gtr:impact>Interviewed for EU funded TV documentarty on Epigenetics

Communicated key ideas to a large lay audience</gtr:impact><gtr:outcomeId>AAAFDEF0DB0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Post Doctoral Fellowship</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>2619642F-8FC5-4BA1-8169-CEF0CC23F661</gtr:id><gtr:outcomeId>5305EA4F1380</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Project Grant Freidreich's ataxia</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Ataxia UK</gtr:fundingOrg><gtr:id>B4036139-0671-47EC-BF51-E456ADB48B2B</gtr:id><gtr:outcomeId>fmy3C5L61Fv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>171000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ataxia UK Project Grant - Restoration of Frataxin gene expression in Friedreich's ataxia - identification and characterisation of novel epigenetic therapies</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Ataxia UK</gtr:fundingOrg><gtr:id>5D2E09CC-5A51-4C5C-9D68-5B38138ACBAD</gtr:id><gtr:outcomeId>030F72321190</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>863446</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Response mode project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AEADF38F-718D-47E7-A9A2-F3F5A610CD67</gtr:id><gtr:outcomeId>Pt6Txwf3emz</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>513746</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EC FP7 (EFACTS)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>6DB3BFE0-0CC5-4639-A1E6-27EA44BE882A</gtr:id><gtr:outcomeId>F59547C36220</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Having shown that the GAA-triplet repeat expansion which occurs in the neurodegenerative disease, Friedreich's ataxia, can induce heterochromatin-mediated silencing we identified histone deacetylase inhibitors that can overcome such silencing in cells from patients.
This has recently been tested in a proof-of-concept study (Libri et al Lancet 2014)</gtr:description><gtr:id>B863D7F1-0982-4E4E-BB87-68581673461E</gtr:id><gtr:impact>We are investigating this finding as a potential treatment with help from an MRC DPFS grant and support from Ataxia UK and the EU FP7 programme.</gtr:impact><gtr:outcomeId>444293E494E</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HDACi</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Identification of an HDAC inhibitor that can upregulate Frataxin in cells from patients with Friedreich's ataxia</gtr:description><gtr:id>60FBCA42-5760-4738-8C0B-CBDB2AAE3995</gtr:id><gtr:impact>Potential as a therapeutic for Friedreich's ataxia which is currently incurable</gtr:impact><gtr:outcomeId>rBkxxrTtSSZ</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HDACi therapy for FRDA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Inserted the triplet-repeat expansion associated with the commonest adult onset muscular dystrophy (Myotonic Dystrophy) into the cognate mouse locus to model the gene expression defect.</gtr:description><gtr:id>DF4D0CD2-55AD-495B-9D28-5094F04ECBBD</gtr:id><gtr:impact>Established improved tractable model for studying gene expression perturbations in triplet-repeat diseases in vivo.</gtr:impact><gtr:outcomeId>9D3B5B1ECA2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CTG -transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Epigenome bioinformatics tool to visualise gene expression profiles simulataneously with genome-wide data provided by chromatin immunoprecipitation.</gtr:description><gtr:id>5EC3BF2F-819D-4738-A8DB-1685E7DC4936</gtr:id><gtr:impact>Has allowed rapid identification an interrogation of regions of the genome responding to epigenetic modifiers</gtr:impact><gtr:outcomeId>2119E17128C</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TROY</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Established a murine model to enable chromatin immunoprecipitation and purification of protein complexes using a biotin-tagged version of heterochromatin-protein 1 expressed in vivo.</gtr:description><gtr:id>882ACEB7-62AF-4981-8B91-33C994DA03BD</gtr:id><gtr:impact>Will enable epigenomic maps to be established for this protein using ex vivo tissue circumventing technical problems the field has faced related to use of antibodies for this purpose.</gtr:impact><gtr:outcomeId>D4EA35E5C9A</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HP1beta-bio</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Murine model to explore function of key chromatin component.</gtr:description><gtr:id>73A175F9-1005-402E-8876-6FBE0D27FA23</gtr:id><gtr:impact>Established that this modifier is a potential modifier of heterochromatin-mediated silencing and triplet-repeat diseases.</gtr:impact><gtr:outcomeId>AA423311E63</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HP1gamma transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Polyclonal antibody specific to histone H3 lysine 4 acetylation</gtr:description><gtr:id>4785D43F-14CD-4B0B-850A-EB9C06765787</gtr:id><gtr:impact>Identification that histone H3 is modified on a key residue, lysine 4, in yeast and mammals. This changes our understanding of how gene's are regulated in eukaryotes as indicated by our genome-wide epigenomic and functional studies.</gtr:impact><gtr:outcomeId>8E6B8B94917</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Identification of histone H3 K4acetylation as a novel post-translational modification using a novel antibody</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Set-up database for patients suffering from Friedreich's ataxia</gtr:description><gtr:id>02D0A570-9972-4DA9-A03D-8D9320F5C2FF</gtr:id><gtr:impact>Obtained PBLs, chromatin and RNA inorder to perform epigenotype/phenotype correlations.</gtr:impact><gtr:outcomeId>D45ED8E529E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>FRDA cohort</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>689724CE-40B2-4C16-9F96-557A16A789EF</gtr:id><gtr:title>Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8300fec9520728389469052e9be7f5"><gtr:id>8b8300fec9520728389469052e9be7f5</gtr:id><gtr:otherNames>Chan PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_14037_27_23474817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A860027-7652-476E-B959-CB81287CD52E</gtr:id><gtr:title>Gene regulation and epigenetics in Friedreich's ataxia.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58930643724f065f0517d82550e47364"><gtr:id>58930643724f065f0517d82550e47364</gtr:id><gtr:otherNames>Yandim C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_14037_27_23859339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F09143F-0454-4620-89DC-D56AC982F33F</gtr:id><gtr:title>Context is everything: activators can also repress.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0354e961de8472449451b121e8d7022a"><gtr:id>0354e961de8472449451b121e8d7022a</gtr:id><gtr:otherNames>Festenstein R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>pm_14037_27_23037592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FAB4FDB-424F-44A9-BE89-2EDD904B8089</gtr:id><gtr:title>H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d489acdd72e8dc0a1791df6383a55df"><gtr:id>1d489acdd72e8dc0a1791df6383a55df</gtr:id><gtr:otherNames>Guillemette B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>Ug7RqGfqtWt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35C81B2E-52F9-4919-B946-4A00437DC6E2</gtr:id><gtr:title>Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.</gtr:title><gtr:parentPublicationTitle>Journal of neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6f617d73d5718ae5f7d8b84c2cea297"><gtr:id>c6f617d73d5718ae5f7d8b84c2cea297</gtr:id><gtr:otherNames>Bishop MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3077</gtr:issn><gtr:outcomeId>gtgSC9tLmHi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E61211DA-4137-4E5C-B443-E1AA88C84DF2</gtr:id><gtr:title>Breaking the silence in Friedreich's ataxia.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0354e961de8472449451b121e8d7022a"><gtr:id>0354e961de8472449451b121e8d7022a</gtr:id><gtr:otherNames>Festenstein R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>B99EF4CCB24</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15540C77-26F1-4893-8CD8-5E8EE5793CF1</gtr:id><gtr:title>The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/709157476448ba4bc6e3a2d5e6e3da71"><gtr:id>709157476448ba4bc6e3a2d5e6e3da71</gtr:id><gtr:otherNames>Manderson AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>4255BD95270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A12AFA3-7F39-4E55-B1D5-6659CE38A1CF</gtr:id><gtr:title>Epigenetic regulation: DNA confers identity but is not enough to maintain it.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f01fe121d20f082b7f44c2d6876a1b"><gtr:id>b1f01fe121d20f082b7f44c2d6876a1b</gtr:id><gtr:otherNames>Poot RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>359C8869A85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D26FC5E2-9168-4D86-989B-CB9C210B10E1</gtr:id><gtr:title>Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d4abefe8b50cd360610b80cdf07d3f6"><gtr:id>9d4abefe8b50cd360610b80cdf07d3f6</gtr:id><gtr:otherNames>Libri V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>54621b4f9e9d25.37555979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C14D58-4A2E-4E6F-96A2-AA21165A0F17</gtr:id><gtr:title>The molecular basis for stability of heterochromatin-mediated silencing in mammals.</gtr:title><gtr:parentPublicationTitle>Epigenetics &amp; chromatin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/011123e0f0e5e6d44a129614d1c92aef"><gtr:id>011123e0f0e5e6d44a129614d1c92aef</gtr:id><gtr:otherNames>Hiragami-Hamada K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1756-8935</gtr:issn><gtr:outcomeId>1FA20F6288A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>723C89CA-2869-4865-B599-7F887042D6CC</gtr:id><gtr:title>Transcription elongation and tissue-specific somatic CAG instability.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5347bc9353596d38395097060bc39cc8"><gtr:id>5347bc9353596d38395097060bc39cc8</gtr:id><gtr:otherNames>Goula AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_14037_27_23209427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E28EE01-0AD0-40E0-9FCB-32A4448DA412</gtr:id><gtr:title>Tissue-dependent regulation of RNAP II dynamics: the missing link between transcription and trinucleotide repeat instability in diseases?</gtr:title><gtr:parentPublicationTitle>Transcription</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5347bc9353596d38395097060bc39cc8"><gtr:id>5347bc9353596d38395097060bc39cc8</gtr:id><gtr:otherNames>Goula AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2154-1272</gtr:issn><gtr:outcomeId>pm_14037_27_23989661</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/182</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>